Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.
Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.
Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.
For more information, please visit www.karyopharm.com.
Karyopharm Therapeutics (KPTI) has commenced a Phase 2 study (XPORT-MF-035) to assess the efficacy of oral selinexor in myelofibrosis patients previously treated with JAK inhibitors. The trial aims to enroll up to 112 patients, evaluating the primary endpoint of spleen volume reduction. This study follows promising results from the ESSENTIAL trial, where 33% of patients experienced significant SVR after 24 weeks of treatment. The company emphasizes its commitment to addressing unmet medical needs in serious conditions like myelofibrosis.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the completion of patient recruitment for the Phase 3 SIENDO study, evaluating selinexor for front-line maintenance therapy in advanced or recurrent endometrial cancer. With over 250 patients enrolled, the study aims to show improved progression-free survival rates. There are currently no approved maintenance therapies for this cancer type. Karyopharm expects to report top-line data by year-end 2021 or early 2022, which could demonstrate selinexor's therapeutic potential and impact future treatment options.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on December 1, 2021, that its Compensation Committee granted stock options for 68,900 shares to 13 new employees, effective November 30, 2021. The options have an exercise price of $6.95 per share, equal to the closing price on the grant date. Each option vests over four years, with 25% vesting after one year, and can be exercised immediately upon termination under certain conditions. This move is part of Karyopharm's strategy to attract talent as it develops novel cancer therapies.
Karyopharm Therapeutics (Nasdaq: KPTI) will host a virtual Investor Day on December 8, 2021, from 10:00 a.m. to 12:30 p.m. ET. The event will feature Karyopharm's executive team and six experts in oncology to discuss commercial opportunities and pipeline priorities. Attendees can join via phone or view a live webcast on the company’s website. Karyopharm specializes in cancer therapies, notably its lead drug XPOVIO®, approved for several hematologic cancers. The event aims to outline the company's vision and milestones.
Karyopharm Therapeutics (Nasdaq: KPTI) announced participation in the Jefferies London Healthcare Conference with CEO Richard Paulson hosting a fireside chat. The discussion will be available for on-demand listening starting November 18, 2021, at 3:00 a.m. Eastern Time. A replay will be accessible for 30 days on the company's investor website.
Karyopharm is focused on developing innovative cancer therapies, particularly through its XPOVIO® (selinexor) compound, which is approved for multiple hematologic malignancies.
Karyopharm Therapeutics (KPTI) announced new data from a Phase 2 study of selinexor, an oral SINE compound for myelofibrosis patients previously treated with JAK inhibitors. The study showed a 33% response rate, with significant spleen volume reduction and improved anemia status. Despite ruxolitinib's poor prognosis (14 months survival), selinexor demonstrated durable responses and a well-tolerated safety profile. Karyopharm plans to initiate a new Phase 2 study evaluating selinexor against physician's choice in late 2021. Results will be presented at the ASH 2021 meeting from December 11-14.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) reported third-quarter 2021 financial results, revealing net product revenue of $26.7 million, a 32% increase from the previous quarter and 25% growth year-over-year. The company highlighted its commercial success with XPOVIO, moving into earlier treatment lines for multiple myeloma. R&D expenses rose to $45.8 million, while the net loss was $51.8 million or $0.69 per share. Karyopharm expects a cash runway into mid-2023, with key upcoming milestones including Phase 3 data from the SIENDO study in endometrial cancer.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the granting of stock options for 171,300 shares to 15 newly-hired employees as of October 29, 2021. This grant, compliant with Nasdaq Listing Rule 5635(c)(4), includes a stock option exercise price of $5.46 per share. The options vest over four years, with 25% vesting at the one-year mark. In instances of a "change in control event," the options are immediately exercisable if employment is terminated for "good reason" or without "cause." Karyopharm specializes in innovative cancer therapies, notably its lead compound, XPOVIO®.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its third quarter 2021 financial results on November 3, 2021. The company's management will host a conference call at 8:30 a.m. ET on the same day to discuss results and updates. Karyopharm focuses on innovative cancer therapies, notably its lead compound, XPOVIO® (selinexor), which is approved for multiple hematologic malignancies in the U.S. and has received conditional authorization in Europe. For details, visit the investor section.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that the first patient has been dosed in the Phase 2 expansion study evaluating eltanexor for myelodysplastic syndrome (MDS). This follows promising Phase 1 results showing a 53% overall response rate and a median overall survival of 9.9 months in high-risk, relapsed MDS patients. The Phase 2 expansion aims to assess eltanexor monotherapy in HMA-refractory MDS patients, with the overall response rate as the primary endpoint. Eltanexor is part of a new approach targeting nuclear export to treat various cancers.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
What is Karyopharm Therapeutics' main focus?
What is XPOVIO® (selinexor)?
What recent achievements has Karyopharm reported?
Who are Karyopharm's global partners?
What are Karyopharm's financial highlights?
What are the key indications for XPOVIO?
What is the significance of Karyopharm's research on nuclear export proteins?
How does Karyopharm support clinical trials and research?
What are the safety considerations for XPOVIO?
How can I get more information about Karyopharm's products or clinical trials?
